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Introduction
Platelet-derived growth factor receptor (PDGFR) is a transmembrane receptor tyrosine kinase.
Upon binding of circulating PDGF ligand, PDGFRα and β subunits homodimerize or heterodimerize, undergo autophosphoryation, and activate downstream signal transduction molecules including phosphoinositide 3-kinase, Ras, phopholipase C-γ, Src, and signal transducer and activator of transcription 1 . In normal physiology, PDGFRα functions in early and late stages of embryonic development (during which it drives proliferation of undifferentiated mesenchymal populations, tissue remodeling, and cellular differentiation), wound healing, angiogenesis, and modulating interstitial fluid pressure [2] [3] .
When expressed on cancer cells, PDGFRα has been implicated in the development and progression of several malignancies 4 . Co-expression of PDGF and PDGFRα has been reported in various cancer types, consistent with autocrine-mediated growth 3 . In lung cancer, expression of PDGF and/or PDGFRα is associated with more aggressive tumor biology and worse prognosis 5 .
Specific genetic alterations of the PDGF-PDGFRα axis occur in gastrointestinal stromal tumors (activating mutations in the intracellular domain of PDGFRα) 6 , certain gliomas and NSCLCs (PDGFRα amplification) [7] [8] , dermatofibrosarcoma protuberans (a 17;22 chromosomal translocation resulting in a fusion oncogene encoding PDGF-B) 9 , and hypereosinophilic syndrome (FIP1L1-PDGFRA fusion transcripts) 10 .
Given the encouraging results achieved with targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in patients with lung tumors harboring EGFR mutations and ALK translocations, recent PDGFRα research has focused on identifying those lung cancers with aberrant tumor cell PDGFRα activity as potential candidates for PDGFRα-directed therapy.
For instance, in a recent screen of NSCLC cell lines, 1 of 103 cell lines responded in vitro to the PDGFR inhibitor sunitinib 11 . The sensitive cell line, H1703, was noted to have high-level PDGFRA amplification. Among the larger set of 637 human tumor-derived cell lines evaluated in the study, only one other, the PDGFRα-positive A-204 rhabdomyosarcoma cell line, responded to sunitinib, suggesting that only rare solid tumor patients might benefit from PDGFRα inhibition.
However, such an approach does not account for the potential therapeutic effects of stromal PDGFRα inhibition. In tumor stroma, the PDGF-PDGFRα axis functions in fibroblast activation, aberrant epithelial-stromal interactions, modulation of tumor interstitial pressure, and production and secretion of vascular endothelial growth factor (VEGF) [12] [13] [14] . In studies with VEGF-null tumorigenic cells, PDGF-AA was identified as the major stromal fibroblast chemotactic factor produced by the tumor cells that lead to recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth
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.
To determine the effects of stromal PDGFRα inhibition, we capitalized on xenograft modeling of cancer (human tumor cells, mouse stromal cells) and the availability of species-specific anti-PDGFRα monoclonal antibodies (mAbs). In this model, IMC-3G3, a fully human anti-human PDGFRα mAb, targets tumor cell PDGFRα
15
, whereas 1E10, a fully human anti-mouse PDGFRα mAb, targets stromal PDGFRα. Our studies demonstrate that targeting stromal PDGFRα has single-agent anti-tumor activity and the potential to enhance the effect of chemotherapy in murine models of lung cancer. The cell lines of xenografts sensitive to targeting stromal PDGFRα expressed a high PDGF-AA/VEGF-A ratio relative to a resistant xenograft line, thus suggesting a potential selection strategy for therapy.
Materials and Methods

Cell Culture
With the exception of A549 which was purchased from the American Type Culture Collection (ATCC), all tumor cell lines were provided by Dr. John Minna (UT Southwestern) 16 . Cell lines were authenticated. Specifically, the identity of each cell line was confirmed by DNA fingerprinting via short tandem repeats using the PowerPlex 1.2 kit (Promega, Madison, WI).
Fingerprinting results were compared to reference fingerprints. All cancer cell lines were grown in a humidified atmosphere with 5% CO 2 , at 37°C in RPMI-1640 medium (Life Technologies Inc., Rockville, MD) supplemented with 5% fetal bovine serum. Each cell line was DNA fingerprinted for provenance using the PowerPlex 1.2 kit (Promega) and confirmed to be the same as the DNA fingerprint library maintained by ATCC and the Minna/Gazdar lab (the primary source of the lines), and confirmed to be free of mycoplasma by e-Myco kit (Boca Scientific).
Using previously generated genomic microarray data (Affymetrix, Inc., Santa Clara, Calif. and Illumina, Inc., San Diego, Calif.), 29 NSCLC cell lines with varying expression of PDGFRα were identified. To confirm microarray findings, selected cells were grown in media, harvested at 70-80% confluency, and lysates extracted. Equal amounts of protein were subjected to SDS-PAGE followed by Western blot analysis with anti-PDGFRα antibodies and detected by chemiluminescence. Additionally, confirmation by quantitative PCR was performed. RNA was prepared using TRIzol (Invitrogen) according to the manufacturer's instructions. The quality of RNA was evaluated using spectrophotometry. The cDNA used for subsequent for PCR was made using iScript (Bio-Rad Laboratories, Hercules, CA). Antibody species specificity was confirmed in a solid-phase blocking assay and cell-based signaling assays. In the solid-phase blocking assay, antibodies were first mixed with a fixed amount of mouse PDGFRα/Fc (50 ng at 0.5 μg/ml, R&D Systems, Minneapolis, MN). The mixture was transferred to 96-well plates precoated with PDGF-AA (100 ng/well), followed by incubation with a goat anti-human Fc antibody-HRP conjugate (Jackson ImmunoResearch).
Plates were read at A 450 nm using a microplate reader (Molecular Devices, Sunnyvale, CA). August 28, 2012; DOI: 10.1158 /1535 Cells were seeded into 100 mm tissue culture dishes and maintained in 15 ml of media for 96 hrs at 5% CO 2 and 37 0 C. At the 96 hr time point, cell monolayers were approximately 85-90% confluent. The media was collected and spun three times at 1,000 x g to remove particulate matter. The concentration of PDGF-AA and VEGF-A in the media was measured by ELISA (Quantikine kits from R&D systems; cat. # DAA00B and DVE00). The cells in the dishes were washed with PBS, removed by trypsin and counted for normalization of growth factor concentration to cell number.
Growth Factor Quantitation
Cell-Signaling Assays
Receptor and downstream signaling molecule phosphorylation assays were performed as described 15 . Cell lysates were prepared in lysis buffer a (150 mM NaCl, 50 mM Tris pH 7.4, 1%
Triton X-100, 1 mM EDTA, 10 mM NaPP i , 50 mM NaF, 1 mM Na 3 VO 4 ) with protease inhibitors August 28, 2012; DOI: 10.1158 /1535 Assays were performed as described previously 21 . Briefly, 500-4,000 cells were allowed to seed for 24 hrs before four-fold serial dilutions of drug were added. The maximum dose was 500 µg/ml (~3300 nM) for IMC-3G3 and 1E10. Cells were incubated for four days then relative cell number was determined by the addition of MTS (Promega, Madison, WI, final concentration 333 μg/ml), incubating for 1 to 3 hours at 37°C and reading absorbance at 490 nm in a plate reader (Spectra Max 190, Molecular Devices, Downington, PA). Each experiment contained eight replicates per concentration and the entire assay was performed in multiple replicates.
MTS Assay
Drug sensitivity curves and IC 50 values were calculated using in-house software (DIVISA).
Animal Studies
Animal studies were conducted according to U. . For the H1703 monotherapy study, mice were randomized into two groups (n = 12) and treated with human IgG (40 mg/kg) or IMC-3G3 (40 mg/kg) three times weekly. There is a precedent in animal studies for antibody treatment at 40 mg/kg to achieve circulating antibody trough levels consistent with those achieved in man. For example, the target serum concentration for IMC-3G3 is hypothesized to be one that maintains concentrations above levels associated with inhibition of the growth of human tumor growth xenograft models in mice (155-258 μg/ml). Results of the PK data from patients in the IMC-3G3 Phase 1 study demonstrate that IMC-3G3 dosing yielded serum concentrations at or above the target trough concentrations 22 .
In the 1E10 plus chemotherapy combination studies in A549 and H1993 xenografts, cohorts of animals with established tumors were randomized into four groups (n = 8) and treated with 1)
vehicle, 2) chemotherapy (cisplatin, 1 mg/kg 1x/week; gemcitabine 25 mg/kg, 2x/week), 3)
1E10, or 4) chemotherapy plus 1E10. Mice were treated by i.p. injection twice weekly for the duration of the study. In each group, on the day of dosing, the first treatment listed above was administered first, followed by the second treatment 30 minutes later. Tumor volumes were evaluated twice weekly. In all xenograft studies, animals were assessed for toxicity (weight loss, death, cage side observations) and tumors were measured twice weekly. Tumor volume was calculated according to the formula π/6 x longest length x perpendicular width 2 . Tumor growth in the treatment groups was compared with a repeated-measures ANOVA.
Tumors were harvested for analysis of growth factors by ELISA and Western blotting. Tumors were homogenized in lysis buffer b (Cell Signaling, cat. no. 9803) supplemented with protease inhibitors (Roche) and PhosStop phosphatase inhibitor (Roche). The lysates were centrifuged twice at 14,000 rpm and the protein concentration for the collected supernatant was determined (Bio-Rad, cat. no. 500-0116).
Statistical Analysis
For cell proliferation assays, sigmoidal dose response curves were fitted and the inhibitory concentrations at 50% (IC 50 ) were calculated using the Weibull model. Tumor volumes and August 28, 2012; DOI: 10.1158 /1535 weights were compared using the Student's t test. For IHC studies, tumors were analyzed and compared by One Way ANOVA, followed by Fisher's LSD PostHoc test for multiple comparisons.
The number of samples in each group was always taken as the number of tissues used in the analysis. For PDGF-CC analysis, Adobe Photoshop 7 was used to determine the mean luminosity of the Western blot protein bands. The mean luminosity of each PDGF-C GFD band was normalized by the mean luminosity of the respective β-actin band. These values were plotted in GraphPad Prism 5, and an unpaired t-test was used to determine significance. All calculated P values are two sided. For all tests, P < 0.05 was considered significant.
Results
NSCLC cell line PDGFRα expression and response to inhibition
PDGFRα expression was evaluated by microarray analysis in a panel of NSCLC cell lines (n = 119) (Fig. 1a) . A subset of these lines (n = 32) were screened for protein expression by Western blot analysis (Supplementary Fig. S1 ). PDGFRα expression was demonstrated in human H1703 NSCLC cells, but not in A549 or H1993 cells or in mouse fibroblasts (3T3 cells and MEFs) ( demonstrated resistance to IMC-3G3, with IC 50 greater than 3300 nM (500 µg/ml) (see Table 1 ).
The PDGFRα-positive H1703 lung cancer line contains both PDGFRα and PDGF-CC gene amplifications and shows a co-dependency on this axis for proliferation Author Manuscript Published OnlineFirst on August 28, 2012; DOI: 10.1158 /1535 this kind is a rare event in human lung cancer cell lines, suggesting that only a limited number of lung tumor patients might benefit from tumor cell PDGFRα inhibition. By contrast, IMC-3G3 did not inhibit proliferation of H1792 cells (IC 50 > 500 µg/mL). These cells overexpress PDGFRα (see Supplementary Fig. S1 ) but not PDGF ligand 11 . This observation suggests that, in the absence of PDGFRα mutation or amplification, overexpression of both ligand and receptor are required for cell autonomous growth.
Characterization of IMC-3G3 and 1E10
We capitalized on the xenograft model (human cancer cells, mouse stromal cells) and speciesspecific monoclonal antibodies to evaluate the effects of inhibiting tumor cell and stromal PDGFRα and PLCγ in H1703 cells was inhibited by IMC-3G3 but not by 1E10 (Fig. 2b) . In contrast, 1E10 but not IMC-3G3 inhibited activation of PDGFRα and the signal transduction mediator PLCγ in PDGF-stimulated mouse fibroblasts in vitro (Fig. 2c) . 1E10 inhibited PDGF-AAinduced phosphorylation of mouse PDGFRα but not PDGF-BB-induced phosphorylation of mouse PDGFRβ (Fig. 2d) .
In vitro and in vivo activity of IMC-3G3 on PDGFRα−positive NSCLC
In vitro, human H1703 cells were sensitive to IMC-3G3 in MTS assay (IC 50 = 10 μg/mL), but were resistant to 1E10 (IC 50 > 1000 μg/mL) (Fig. 3a) . Additionally, IMC-3G3 significantly inhibited growth of H1703 xenografts (P = 0.0003, Fig. 3b In vivo anti-tumor activity of 1E10 on PDGFRα-negative xenografts with high PDGF-AA/VEGF-
A ratio
Given that PDGF-AA has been identified as a major stromal fibroblast chemotactic factor produced by tumor cells 14 , it may be assumed that xenograft lines that express high PDGF-AA would have a greater dependence on stromal activation for growth. Therefore, thirteen lung cancer cell lines were screened for PDGF-AA expression to identify lines for in vivo anti-tumor studies targeting stromal PDGFRα. Specifically, the cell lines were grown in vitro and expressed PDGF-AA was measured from the supernatants ( Table 1) . Two lines expressing the highest PDGF-AA were chosen for in vivo therapeutic studies of 1E10. In A549 and Calu-6 xenografts, 1E10 treatment attenuated tumor growth, demonstrating a significant therapeutic effect of 2012; DOI: 10.1158 /1535 stromal targeting (Fig. 4) . In Calu-6 xenografts, average tumor size on Day 32 was 1273 ± 187 mm 3 with 1E10 treatment, compared to 2483 ± 302 mm 3 with control IgG (P=0.002) (Fig. 4a) . In A549 xenografts, average tumor size on Day 36 was 632 ± 65 mm 3 with 1E10 treatment, compared to 960 ± 93 mm 3 with control IgG (P=0.01) (Fig. 4b) . 1E10 also enhanced the effect of cisplatin-gemcitabine chemotherapy in A549 xenografts (Fig. 4c) . Table 1) .
Targeting of stromal PDGFRα with 1E10 had no activity as a monotherapy on the H1993 xenograft (Fig. 4d) . In addition, 1E10 did not enhance the effect of cisplatin-gemcitabine chemotherapy in H1993 xenografts (final weights: control IgG 0.79 ± 0.09 g, 1E10 0.78 ± 0.06 g, cisplatin-gemcitabine 0.28 ± 0.05 g, cisplatin-gemcitabine plus 1E10 0.26 ± 0.07 g) (Fig. 4d) . This cell line resistant to stromal PDGFRα inhibition had an elevated VEGF-A/PDGF-AA ratio of 65.86
( Table 1) . Also of note, in the H1993 xenografts, chemotherapy alone inhibited tumor growth, but A549 xenografts were resistant to the same regimen. . These results echo those of earlier reports suggesting that therapeutic stromal effects, which become apparent in animal models, might otherwise go unrecognized in cell culture assays 25 26 .
Potential explanations for the therapeutic outcome of stromal-PDGFR targeting include effects on fibroblast activation and angiogenesis 12, 14, 27 . In a previous report, PDGF-AA, which binds PDGFRα but not PDGFRβ, was demonstrated to be the major stromal fibroblast chemotactic factor produced by VEGF-null tumorigenic cells 14 . In that system it was concluded that PDGFRα signaling is required for the recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth. In the present study, tumor cell PDGF-AA and VEGF expression levels suggested an explanation as to why only certain lines responded to stromal PDGFRα inhibition. . That 1E10 significantly improved the effect of cisplatin-gemcitabine in the A549 xenografts might suggest reduction of tumor interstitial pressure and enhanced chemotherapy delivery. PDGF-activated stromal fibroblasts synthesize collagen, express matrix metalloproteinases, and form a connective tissue network, all of which promote tumor development [31] [32] [33] . Although the present experiments do not elucidate a therapeutic mechanism of stromal PDGFRα inhibition, it is unlikely that the observed in vivo effects represent a non-stromal mechanism. The possibility that PDGFRα-negative cell lines adapt to express PDGFRα in vivo was considered. However, no human PDGFRα was detected in tumor lysates, and the anti-human PDGFRα antibody IMC-3G3 had no effect on A549 xenograft tumor growth (data not shown). seen when tyrosine kinase inhibitors were combined with chemotherapy, but the addition of a monoclonal antibody to chemotherapy improved overall survival [40] [41] [42] [43] [44] .
The implication that stromal PDGFR targeting could add benefit to NSCLC therapy is substantial.
The overwhelming majority of NSCLCs feature stromal PDGFR expression 5, [45] [46] . Our findings support the possibility that the therapeutic effects of stromal PDGFRα inhibition may reach beyond the rare cancers sensitive to cancer-cell PDGFRα targeting. In general, stromal targets have a number of favorable properties. They are less prone to mutation than are cancer cell 
